{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:34:42Z","timestamp":1773833682494,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.autrev.2024.103538","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T16:46:06Z","timestamp":1711730766000},"page":"103538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The \u2018whole landscape\u2019 of research on systemic sclerosis over the past 73\u00a0years"],"prefix":"10.1016","volume":"23","author":[{"given":"Meng-Di","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Yuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Quan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Guang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Di","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2024.103538_bb0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02347-2021","article-title":"Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease [J]","volume":"60","author":"Birnhuber","year":"2022","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.autrev.2024.103538_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial [J]","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103538_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00060-6","article-title":"Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial [J]","volume":"3","author":"Thombs","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0020","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways [J]","volume":"10","author":"Lopez-Isac","year":"2019","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.autrev.2024.103538_bb0025","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis [J]","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2024.103538_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015816","article-title":"Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension [J]","volume":"10","author":"Tran-Duy","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.autrev.2024.103538_bb0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/1756-185X.14261","article-title":"Clinical features and prognostic factors of systemic sclerosis in Guangxi, China: Retrospective, single-center study of long-term survival in 470 patients [J]","volume":"25","author":"Chen","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"10373","key":"10.1016\/j.autrev.2024.103538_bb0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis [J]","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103538_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104883","article-title":"High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies [J]","volume":"98","author":"Al-Adwi","year":"2023","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.autrev.2024.103538_bb0050","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41584-023-01032-1","article-title":"Back to the future: targeting the extracellular matrix to treat systemic sclerosis [J]","volume":"19","author":"Leask","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103538_bb0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/S40037-021-00695-4","article-title":"Bibliometrics: Methods for studying academic publishing [J]","volume":"11","author":"Ninkov","year":"2022","journal-title":"Perspect Med Educ"},{"issue":"4","key":"10.1016\/j.autrev.2024.103538_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3163\/1536-5050.103.4.013","article-title":"Bibliometrics basics [J]","volume":"103","author":"Cooper","year":"2015","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.autrev.2024.103538_bb0065","article-title":"Schizophrenia and Inflammation Research: A Bibliometric Analysis [J]","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103538_bb0070","doi-asserted-by":"crossref","first-page":"1030377","DOI":"10.3389\/fbioe.2022.1030377","article-title":"Knowledge domain and hotspots analysis concerning applications of two-photon polymerization in biomedical field: A bibliometric and visualized study [J]","volume":"10","author":"Fu","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.autrev.2024.103538_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.121567","article-title":"A scientometric analysis and recent advances of emerging chitosan-based biomaterials as potential catalyst for biodiesel production: A review [J]","volume":"325","author":"Prabakaran","year":"2024","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.autrev.2024.103538_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100480","article-title":"How has the field of metastatic breast cancer in bones evolved over the past 22 years? [J]","volume":"40","author":"Chen","year":"2023","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.autrev.2024.103538_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102129","article-title":"Neuropsychiatric disturbances in mild cognitive impairment: A scientometric analysis [J]","volume":"92","author":"Amrapala","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"10","key":"10.1016\/j.autrev.2024.103538_bb0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5306\/wjco.v14.i10.420","article-title":"What should be the future direction of development in the field of prostate cancer with lung metastasis? [J]","volume":"14","author":"Huang","year":"2023","journal-title":"World J Clin Oncol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103538_bb0095","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/art.22759","article-title":"Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis [J]","volume":"56","author":"Huber","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2024.103538_bb0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score [J]","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103538_bb0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis [J]","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103538_bb0110","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4270","article-title":"Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide [J]","volume":"15","author":"Villano","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","article-title":"Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group [J]","volume":"20","author":"Adler","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"9243","key":"10.1016\/j.autrev.2024.103538_bb0120","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(00)03212-8","article-title":"NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis [J]","volume":"356","author":"Tuveri","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2024.103538_bb0125","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1093\/rheumatology\/keaa136","article-title":"Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study [J]","volume":"59","author":"Campochiaro","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2024.103538_bb0130","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound [J]","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002850","article-title":"Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study [J]","volume":"9","author":"Campochiaro","year":"2023","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.autrev.2024.103538_bb0140","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/annrheumdis-2019-215119","article-title":"Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis [J]","volume":"78","author":"Mor","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl 65","key":"10.1016\/j.autrev.2024.103538_bb0145","first-page":"S40","article-title":"Is there a role for TNFalpha antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique [J]","volume":"29","author":"Distler","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103538_bb0150","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/acr.25038","article-title":"Assessment of the Systemic Sclerosis-Associated Raynaud\u2019s Phenomenon Questionnaire: Item Bank and Short-Form Development [J]","volume":"75","author":"Yu","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103538_bb0155","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/rheumatology\/keac557","article-title":"Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease [J]","volume":"62","author":"Roofeh","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103538_bb0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.22551","article-title":"The Pediatric Rheumatology European Society\/American College of Rheumatology\/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis [J]","volume":"57","author":"Zulian","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2024.103538_bb0165","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis [J]","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.autrev.2024.103538_bb0170","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/art.24494","article-title":"Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis [J]","volume":"60","author":"Hemmatazad","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2024.103538_bb0175","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group [J]","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2024.103538_bb0180","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study [J]","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103538_bb0185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/annrheumdis-2014-206234","article-title":"Tribbles homologue 3 stimulates canonical TGF-beta signalling to regulate fibroblast activation and tissue fibrosis [J]","volume":"75","author":"Tomcik","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103538_bb0190","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis [J]","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2024.103538_bb0195","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks: Data from a randomized controlled trial [J]","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103538_bb0200","first-page":"161","article-title":"Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials [J]","volume":"38 Suppl 125","author":"Bruni","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0205","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-021-02573-0","article-title":"An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod [J]","volume":"23","author":"Hesselstrand","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000826","article-title":"Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features [J]","volume":"5","author":"Hoffmann-Vold","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.autrev.2024.103538_bb0215","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/23971983231163413","article-title":"Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation\/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment [J]","volume":"8","author":"Bruni","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0220","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index [J]","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103538_bb0225","article-title":"Hotspots and future directions in rheumatoid arthritis-related cardiovascular disease: A scientometric and visualization study from 2001 to 2021 based on Web of Science [J]","volume":"9","author":"Wen","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.autrev.2024.103538_bb0230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/08916939008998420","article-title":"Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease [J]","volume":"6","author":"Passaleva","year":"1990","journal-title":"Autoimmunity"},{"issue":"6","key":"10.1016\/j.autrev.2024.103538_bb0235","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/annrheumdis-2011-200986","article-title":"Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis [J]","volume":"71","author":"Manetti","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103538_bb0240","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative [J]","volume":"72","author":"Van Den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis [J]","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0250","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/33.1.90","article-title":"Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases [J]","volume":"33","author":"Denton","year":"1994","journal-title":"Br J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103538_bb0255","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial [J]","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103538_bb0260","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rheumatology\/38.4.309","article-title":"Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud\u2019s phenomenon [J]","volume":"38","author":"Denton","year":"1999","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2024.103538_bb0265","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/ard.2008.096123","article-title":"An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis [J]","volume":"68","author":"Denton","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103538_bb0270","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud\u2019s phenomenon attack frequency in limited cutaneous systemic sclerosis [J]","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2024.103538_bb0275","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and Patent-2 [J]","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0280","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial [J]","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.autrev.2024.103538_bb0285","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2397198319841842","article-title":"Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease [J]","volume":"4","author":"Wollin","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression [J]","volume":"9","author":"Khanna","year":"2023","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.autrev.2024.103538_bb0295","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial [J]","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.autrev.2024.103538_bb0300","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"Stratus: A phase II study of abituzumab in patients with systemic sclerosis-associated interstitial lung disease [J]","volume":"48","author":"Khanna","year":"2021","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103538_bb0305","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1093\/rheumatology\/keab273","article-title":"Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients [J]","volume":"60","author":"Suleman","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2024.103538_bb0310","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1093\/rheumatology\/kead012","article-title":"A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS) [J]","volume":"62","author":"Griffiths-Jones","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2024.103538_bb0315","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS) [J]","volume":"35 Suppl 106","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103538_bb0320","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial [J]","volume":"79","author":"Seibold","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2024.103538_bb0325","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/rheumatology\/kez583","article-title":"Extracellular SPARC cooperates with TGF-beta signalling to induce pro-fibrotic activation of systemic sclerosis patient dermal fibroblasts [J]","volume":"59","author":"Carvalheiro","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103538_bb0330","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/rheumatology\/keac578","article-title":"The role of B cells in the pathogenesis of systemic sclerosis: an update [J]","volume":"62","author":"Sakkas","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2024.103538_bb0335","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/art.41798","article-title":"B cell depletion inhibits fibrosis via suppression of profibrotic macrophage differentiation in a mouse model of systemic sclerosis [J]","volume":"73","author":"Numajiri","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0340","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear Antibodies in Systemic Sclerosis: an Update [J]","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2024.103538_bb0345","first-page":"10","article-title":"The Fibrosis and Immunological Features of Hypochlorous Acid Induced Mouse Model of Systemic Sclerosis [J]","volume":"2019","author":"Meng","year":"1861","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103538_bb0350","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers [J]","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2024.103538_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.923869","article-title":"Positron emission tomography to improve assessment of interstitial lung disease in patients with systemic sclerosis eligible for autologous stem cell transplantation [J]","volume":"13","author":"Broens","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103538_bb0360","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fphar.2020.00767","article-title":"Polyporus polysaccharide ameliorates bleomycin-induced pulmonary fibrosis by suppressing myofibroblast differentiation via TGF-beta\/Smad2\/3 Pathway [J]","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103538_bb0365","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.semarthrit.2020.06.003","article-title":"The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis [J]","volume":"50","author":"Volkmann","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2024.103538_bb0370","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41419-021-04248-9","article-title":"The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease [J]","volume":"12","author":"Jamadar","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2024.103538_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.935787","article-title":"Autoimmunity to sphingosine-1-phosphate-receptors in systemic sclerosis and pulmonary arterial hypertension [J]","volume":"13","author":"Gluschke","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0380","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-022-02734-9","article-title":"Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension [J]","volume":"24","author":"Kolstad","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0385","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13075-022-02835-5","article-title":"Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis [J]","volume":"24","author":"Mukherjee","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2024.103538_bb0390","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","article-title":"Systemic sclerosis in adults. Part I: Clinical features and pathogenesis [J]","volume":"87","author":"Jerjen","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103538_bb0395","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13075-019-2072-y","article-title":"Complex assessment of bone mineral density, fracture risk, vitamin D status, and bone metabolism in Hungarian systemic sclerosis patients [J]","volume":"21","author":"Horvath","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2024.103538_bb0400","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-017-0684-2","article-title":"Very early systemic sclerosis and pre-systemic sclerosis: definition, recognition, clinical relevance and future directions [J]","volume":"19","author":"Bellando-Randone","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.autrev.2024.103538_bb0405","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/BOR.0000000000000903","article-title":"Insights into molecular and clinical characteristics of very early systemic sclerosis [J]","volume":"34","author":"Bellando-Randone","year":"2022","journal-title":"Curr Opin Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:26:12Z","timestamp":1716243972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1568997224000296"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103538","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u2018whole landscape\u2019 of research on systemic sclerosis over the past 73\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103538"}}